GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » ROC (Joel Greenblatt) %

Opus Genetics (STU:R3X1) ROC (Joel Greenblatt) % : 0.00% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Opus Genetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Opus Genetics's ROC (Joel Greenblatt) % or its related term are showing as below:

STU:R3X1' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -472425   Med: -98738.89   Max: 227650
Current: -884.33

During the past 5 years, Opus Genetics's highest ROC (Joel Greenblatt) % was 227650.00%. The lowest was -472425.00%. And the median was -98738.89%.

STU:R3X1's ROC (Joel Greenblatt) % is ranked worse than
66.1% of 1410 companies
in the Biotechnology industry
Industry Median: -307.055 vs STU:R3X1: -884.33

Opus Genetics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Opus Genetics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Opus Genetics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics ROC (Joel Greenblatt) % Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-21,420.00 -91,306.25 -477,828.57 229,226.67 -152,433.33

Opus Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 822.38 -357.32 - - -

Competitive Comparison of Opus Genetics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Opus Genetics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opus Genetics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Opus Genetics's ROC (Joel Greenblatt) % falls into.



Opus Genetics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.262 + 0 + 1.035) - (3.831 + 0 + 0.069)
=-1.603

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.673 + 0 + 0.386) - (5.42 + 0 + 0.066)
=-3.427

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Opus Genetics for the quarter that ended in Sep. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-27.124/( ( (0 + max(-1.603, 0)) + (0 + max(-3.427, 0)) )/ 1 )
=-27.124/( ( 0 + 0 )/ 1 )
=-27.124/0
= %

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opus Genetics  (STU:R3X1) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Opus Genetics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Opus Genetics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Opus Genetics Business Description

Traded in Other Exchanges
Address
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Headlines

No Headlines